Month: March 2020

Phase 1b/2 clinical trial of ALRN-6924 as a myelopreservation agent for the protection against chemotherapy-induced toxicity in small cell lung cancer started dosing patients September 2019; interim data suggests reduction in severe anemia and thrombocytopenia; encouraging results led to the plan to test second dosing schedule to assess if effects can be extended to reduction in severe neutropeniaWATERTOWN, Mass., March 30, 2020 (GLOBE NEWSWIRE) — Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2019.“We continue to advance our lead clinical program evaluating ALRN-6924 as an agent that protects patients with p53-mutant cancers against chemotherapy-induced...

LA JOLLA, Calif., March 30, 2020 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced it has entered into a common stock purchase agreement for up to $15 million with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor. Under the terms of the purchase agreement, and once a registration statement relating to the transaction has been declared effective, Equillium will have the right at its sole discretion, but not the obligation, to sell to LPC up to $15 million worth of shares of its common stock over the 36-month term of the agreement. The price of Equillium’s shares of common stock sold is as set forth in the purchase agreement and...

AUSTIN, Texas, March 30, 2020 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”, “Plus”), today announced financial and business results for its Fourth Quarter and full Fiscal Year ended December 31, 2019.Fiscal 2019 Fourth Quarter net income from continuing operations was $0.92 million, or $0.12 per share. Total net income for the quarter after factoring in discontinued operations was $0.88 million, or $0.11 per share. Net cash provided by operating activities for Q4 was approximately $1.03 million. Plus ended Q4 with approximately $17.6 million of cash and cash equivalents.For the year ended December 31, 2019, net loss from continuing operations was ($3.3) million, or ($2.77) per share. Total net loss for the year after factoring in discontinued operations was ($10.9) million, or ($8.27) per share. Net cash...

HOUSTON, March 30, 2020 (GLOBE NEWSWIRE) — C-Bond Systems, Inc. (the “Company” or “C-Bond”) (OTC: CBNT), a nanotechnology solutions company, will host a virtual roadshow webinar on April 7, 2020 at 11:30 a.m. Eastern Time.Scott R. Silverman, Chairman and Chief Executive Officer of C-Bond, will present an overview of the business model and growth initiatives. The webinar will be accompanied by a presentation and followed by a question and answer session, which can be accessed via the webcast link or dial-in numbers below.To access the webinar, please use the following information:Date: Tuesday, April 7, 2020       Time: 11:30 a.m. Eastern Time   Dial-in: 1-888-254-3590 International Dial-in: 1-323-994-2093      Conference Code: 7022707         Webcast:  http://public.viavid.com/index.php?id=138521A telephone replay will be available...

DAVIS, Calif., March 30, 2020 (GLOBE NEWSWIRE) — Marrone Bio Innovations, Inc. (Nasdaq: MBII) (MBI),  a leading provider of effective and environmentally responsible pest management and plant health products, announced today that its Form S-1 resale registration statement relating to the potential resale of shares of common stock, including common stock issuable upon the exercise of warrants, held by certain shareholders of the Company has been declared effective by the U.S. Securities and Exchange Commission (“SEC”) on March 30, 2020.“This registration statement was filed to comply with the terms of our private placement and debt refinancing transactions that we completed in February 2018, as well as the warrant financing transactions we previously announced in August 2019,” said Jim Boyd, the Company’s Chief...

VANCOUVER and MINNEAPOLIS, March 30, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, the Tiara™ (“Tiara”), and minimally invasive devices for the treatment of refractory angina, the Neovasc Reducer™ (“Reducer”) today reported financial results for the fourth quarter and full year ending December 31, 2019. Recent Highlights Delivered 20% full year over year revenue growth for the Reducer Submitted Reducer premarket approval (“PMA”) application on schedule on December 30, 2019 Reducer added to the European Society of Cardiology Guidelines as treatment option for chest pain Added further industry veteran to team, as Bill Little joined as Chief...

BEIJING, March 30, 2020 (GLOBE NEWSWIRE) — ATA Creativity Global (“ACG” or the “Company”, Nasdaq: AACG), an international education services provider focused on quality experiences that cultivate and enrich students’ creativity, today announced preliminary unaudited financial results for the quarter and year ended December 31, 2019 (“Fourth Quarter 2019” and “Fiscal Year 2019,” respectively).2019 Fourth Quarter and Annual Highlights, Significant Changes in Operations Due to Huanqiuyimeng AcquisitionACG completed the acquisition (“Huanqiuyimeng Acquisition”) of Beijing Huanqiuyimeng Education Consultation Corp. (“Huanqiuyimeng”), a leading provider of educational services for students in China interested in applying for overseas art study and now a wholly owned subsidiary of ACG. Control of Huanqiuyimeng transitioned to ACG on August...

DENVER, Col., March 30, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Helix Technologies, Inc. (OTCQB:HLIX) (the “Company”) today reported its results for the fourth quarter and fiscal year 2019. The Company will be hosting an earnings call today, March 30, 2020, at 4:30pm Eastern time. Call info can be found at the bottom of this release.“2019 was a pivotal year for Helix Technologies.  We made tremendous progress in rolling out our fully integrated suite of services, improved every metric across the business, expanded market share across business lines and assembled one of the strongest management teams in the industry,” said Helix Technologies CEO and Executive Chairman Zachary L. Venegas.  “By continuing to deliver strong operating outcomes on our strategic plan focused on critical infrastructure, we have positioned ourselves...

OMAHA, Neb., March 30, 2020 (GLOBE NEWSWIRE) — Werner Enterprises, Inc. (NASDAQ: WERN), one of the nation’s largest transportation and logistics companies, will release its first quarter 2020 earnings on Tuesday, April 28, 2020, after the market close. The company will also hold a conference call to discuss the first quarter 2020 results and updated 2020 outlook on the same day, beginning at 4:00 p.m. CT.The news release, live webcast of the earnings conference call, and accompanying slide presentation will be available at www.werner.com in the “Investors” section under “Webcasts & Presentations.” To participate on the conference call, please dial (844) 701-1165 (domestic) or (412) 317-5498 (international). Please mention to the operator that you are dialing in for the Werner Enterprises call.A replay of the conference call...

Commercial launch on track, including the Pure-Vu® System placed in more than 15 major U.S. hospitals since Q4 2019More than 50 GI physicians trained on the new Pure-Vu® System technology since launchKey regulatory milestone achieved as GEN2 Pure-Vu® System awarded CE mark approvalAnnounced cost reduction plan due to unprecedented market conditions related to Covid-19 pandemicFORT LAUDERDALE, Fla., March 30, 2020 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today reported its financial results for the fourth quarter and year ended December 31, 2019, and provided a corporate...